November 4, 2025
Integrated Cross-Functional Review Strengthens Readiness for IND-Enabling Completion and Clinical Entry
Atlanta, GA — November 2025 — OncoSpherix, a biotechnology company advancing novel therapeutics targeting hypoxia-related oncogenic mechanisms, today convened its full leadership, scientific, and advisory team at Portal Innovations in Atlanta. The meeting brought together the company’s Board of Directors, scientific founders, operational leadership, clinical partners, external advisors, and representatives from the Georgia Research Alliance to review progress across programs and align on strategic priorities for the upcoming year.
The session provided a comprehensive review of the company’s scientific, clinical, regulatory, and operational activities, ensuring integration and oversight across all functional areas as OncoSpherix prepares for major development milestones anticipated in 2026 and 2027.
Key discussion areas included:
- Ongoing advancement of discovery and preclinical development activities
- Updates on formulation, pharmacology, and toxicology planning
- Clinical development strategy for first-in-human evaluation
- Regulatory preparation for upcoming submissions
- Operational readiness, including program resourcing and partner coordination
- Financial planning and investment strategy to support upcoming milestones
Margaret Offermann, MD, PhD, CEO of OncoSpherix, emphasized the importance of cross-functional alignment as the company prepares to enter the next phase of development.
“The comprehensive engagement across our scientific, clinical, business and legal teams reflects the coordinated and disciplined approach we are taking as we advance toward first-in-human studies. The clarity and rigor demonstrated at today’s meeting reinforce our confidence in the path ahead,” said Dr. Offermann.
Dr. Russell Medford, Chairman of the Board, highlighted the scientific progress and the company’s readiness for the next stage of execution.
“The continued progress across our programs demonstrates the strength of the OncoSpherix platform and the commitment of our team and partners. As we prepare for significant milestones in 2026, the Board remains highly encouraged by the maturation of the science, the quality of the data generated to date, and the well-structured development strategy presented today,” stated Dr. Medford.
The company will continue to advance its lead programs toward IND-enabling completion, regulatory submissions, and initiation of clinical development while expanding key partnerships that support its scientific and operational objectives.
About OncoSpherix:
OncoSpherix, Inc., based in Atlanta, GA, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supplies, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candidate has been shown in mouse models to reduce primary tumor growth, inhibit metastasis, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). OncoSpherix intends to advance its lead candidate in one or more of these indications.
Company Contact:
Allan Valmonte
VP of Business Operations
Source: OncoSpherix, Inc.
